|
Jan 31
|
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
|
|
Jan 30
|
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
|
|
Jan 29
|
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
|
|
Jan 29
|
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
|
|
Jan 28
|
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
|
|
Jan 28
|
Sage rejects Biogen’s $469m takeover bid
|
|
Jan 27
|
Sector Update: Health Care Stocks Gain Late Afternoon
|
|
Jan 27
|
Sage rebuffs Biogen bid to take it over
|
|
Jan 27
|
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
|
|
Jan 27
|
Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosing
|
|
Jan 26
|
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
|
|
Jan 26
|
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
|
|
Jan 4
|
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
|
|
Jan 2
|
Is Eli Lilly Stock A Buy After FDA Pushes Back On Compounded Knockoffs?
|
|
Jan 2
|
Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges
|
|
Jan 1
|
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
|
|
Jan 1
|
The 5 worst performing stocks on the Nasdaq 100 in 2024
|